Dr Cecilia Moore
Dr Cecilia Moore
Top Publications
- Turkova, A, Moore, CL, Butler, K, Compagnucci, A, Saïdi, Y, Musiime, V, Nanduudu, A, Kaudha, E, Cressey, TR, Chalermpantmetagul, S, et al. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial. PLOS ONE 13(4) : e0196239 2024 view publication
- Amin, J, Boyd, MA, Kumarasamy, N, Moore, CL, Losso, MH, Nwizu, CA, Mohapi, L, Kerr, SJ, Sohn, AH, Teppler, H, et al. Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection. PLOS ONE 10(2) : e0118228 2024 view publication
- Moore, CL, Amin, J, Gidding, HF, Law, MG. A New Method for Assessing How Sensitivity and Specificity of Linkage Studies Affects Estimation. PLOS ONE 9(7) : e103690 2024 view publication
- Martin, A, Moore, CL, Mallon, PWG, Hoy, JF, Emery, S, Belloso, WH, Phanuphak, P, Ferret, S, Cooper, DA, Boyd, MA. HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy. PLOS ONE 8(10) : e77138 2024 view publication
- Messina, NL, Sperotto, MG, Puga, MAM, da Silva, PV, de Oliveira, RD, Moore, CL, Pittet, LF, Jamieson, T, Dalcolmo, M, dos Santos, G, et al. Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination. Frontiers in Immunology 14: 1172851 2024 view publication
Page 1 of 7
Career information
Share //
